Pasi A. Jänne, MD, PhD, FASCO - Translating the Latest Evidence on First-Line Treatment for EGFR-Mutated NSCLC Into Practice: An Update for Community Clinicians

Please visit answersincme.com/ZMN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in the management of non–small-cell lung cancer (NSCLC) discusses first-line treatment of advanced EGFR-mutated NSCLC. Upon completion of this activity, participants should be better able to: Review current guideline recommendations for the first-line treatment of advanced EGFR-mutated NSCLC; Describe the clinical implications of the latest evidence on first-line therapeutic strategies for advanced EGFR-mutated NSCLC; and Outline evidence-based strategies to personalize first-line therapeutic selection for patients with advanced EGFR-mutated NSCLC.